How liver membrane fats control insulin's effects
Novel regulation of insulin action in the liver
Researchers are looking at whether changes in liver membrane lipids driven by the enzyme Lpcat3 change how insulin controls blood sugar and fat in adults with type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project ID | NIH-11286800 on NIH RePORTER |
What this research studies
This project focuses on an enzyme called Lpcat3 that shapes the types of fats (phospholipids) in liver cell membranes and how those membrane changes affect insulin signaling. Scientists will manipulate Lpcat3 levels in cells and animal models to change membrane fluidity and measure insulin-driven processes such as suppression of glucose production, fat production, and triglyceride secretion. They will examine molecular signals like SREBP-1c processing and downstream insulin pathways to link membrane composition to selective insulin resistance. The goal is to define mechanisms in the liver that may explain why insulin controls glucose and lipids differently in type 2 diabetes.
Who could benefit from this research
Good fit: Adults with type 2 diabetes who are concerned about liver-related insulin resistance are the population most directly related to this research and could be candidates for future translational trials based on these findings.
Not a fit: People with type 1 diabetes or those whose high blood sugar is driven mainly by non-liver causes may not benefit directly from findings focused on liver membrane remodeling.
Why it matters
Potential benefit: If successful, this work could point to new targets for therapies that restore normal insulin action in the liver and improve blood sugar and lipid control in type 2 diabetes.
How similar studies have performed: Prior preclinical studies have linked Lpcat3 to liver lipid metabolism and membrane composition, but applying these findings to correct insulin resistance is a relatively new area mainly tested in cells and animal models so far.
Where this research is happening
Champaign, United States
- University of Illinois at Urbana-Champaign — Champaign, United States (Active)
Researchers
- Principal investigator: Wang, Bo — University of Illinois at Urbana-Champaign
- Study coordinator: Wang, Bo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.